Combined small-cell lung carcinoma
J Qin, H Lu - OncoTargets and therapy, 2018 - Taylor & Francis
Currently, studies assessing combined small-cell lung carcinoma (C-SCLC) are relatively
scarce and limited. Indeed the clinicopathological features, treatment, and prognosis of …
scarce and limited. Indeed the clinicopathological features, treatment, and prognosis of …
[HTML][HTML] Combined small cell carcinoma of the lung: is it a single entity?
X Zhao, JN McCutcheon, B Kallakury… - Journal of Thoracic …, 2018 - Elsevier
Background SCLC accounts for 15% and 20% of all lung cancers, with combined SCLC
(CSCLC) comprising 2% to 5%. Little is known about the clinical characteristics and …
(CSCLC) comprising 2% to 5%. Little is known about the clinical characteristics and …
[HTML][HTML] Combined small cell lung cancer: current progress and unmet needs
C Zeng, G Qiu, X Xie, T Liu, Z Chen… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Combined small cell lung cancer (CSCLC) is a specific subtype of lung cancer characterized
by a pathological mixture of small cell lung cancer and any subtype of non-small cell lung …
by a pathological mixture of small cell lung cancer and any subtype of non-small cell lung …
[HTML][HTML] Clinical outcomes of surgically resected combined small cell lung cancer: a two-institutional experience
C Zhang, H Yang, H Zhao, B Lang, X Yu… - Journal of thoracic …, 2017 - ncbi.nlm.nih.gov
Background The combined small cell lung cancer (c-SCLC) was rare and its
clinicopathological characteristics had not been thoroughly described. The aim of this study …
clinicopathological characteristics had not been thoroughly described. The aim of this study …
Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined Small-Cell Lung Cancer: A Retrospective Study
Z Shi, J Wei, W Sun, X Zeng, H Zhou, Z Song - Clinical Lung Cancer, 2023 - Elsevier
Background Combined small-cell lung cancer (c-SCLC) with gene mutations is a rare
subtype often found alongside adenocarcinoma. Targeted therapy may be effective because …
subtype often found alongside adenocarcinoma. Targeted therapy may be effective because …
CACA guidelines for holistic integrative management of lung cancer
J Wang - Holistic Integrative Oncology, 2024 - Springer
Lung cancer (LC) is among the malignant tumors with the highest disease burden in the
world, accounting for approximately 11.4% of all cancer cases, and LC was the 2nd most …
world, accounting for approximately 11.4% of all cancer cases, and LC was the 2nd most …
Genetic and immunohistochemical studies investigating the histogenesis of neuroendocrine and carcinomatous components of combined neuroendocrine carcinoma
M Iijima, T Yokobori, A Mogi, K Shimizu… - Annals of Surgical …, 2019 - Springer
Background Lung combined neuroendocrine carcinomas (NECs) comprise NEC and non-
NEC components, such as adenocarcinoma and squamous cell carcinoma. Mutation of …
NEC components, such as adenocarcinoma and squamous cell carcinoma. Mutation of …
混合型小细胞肺癌外科治疗后预后分析
韩轲， 杨海棠， 范力文， 赵珩 - 中国肿瘤临床, 2017 - cqvip.com
目的: 探索混合型小细胞肺癌(C-SCLC) 术后患者生存的预后影响因素. 方法: 回顾性分析2010
年1 月至2014 年12 月在上海交通大学附属胸科医院行肺癌根治性切除及系统性淋巴结清扫C …
年1 月至2014 年12 月在上海交通大学附属胸科医院行肺癌根治性切除及系统性淋巴结清扫C …
